“Brexit could provide UK Life Sciences with the opportunity to become a global leader in the uptake of innovative medicines”
A new white paper by IQVIA and Public Policy Projects (PPP) analyses the ability of the Life Sciences Industrial Strategy and Sector Deal to meet the challenges raised by Brexit. Where there are gaps, it specifically calls on the Government to place these issues at the centre of the deal it seeks during negotiations with EU partners. The white paper demonstrates the value of medicines through the use of Real-World Evidence and how the UK’s unique health data ecosystem can position it as the global leader in this evolving science, benefitting NHS patients and payers alike.
It makes 9 recommendations:
- The UK should continue to have a 'deep and special relationship' with the EU, including membership of the EMA
- The UK needs to secure free trade and free movement of medicines with the EU
- The UK government should commit to making non-identified patient-level data more readily available for appropriate commercial research
- The UK should position itself as a destination for inward pharmaceutical investment
- The UK government should consult and introduce clinical research performance metrics aligned with global standards to improve clinical trial success rates and predictability
- The UK should maintain access arrangements for the best talent from across the global scientific community
- The UK government should increase spending on research to 2.4 per cent of GDP by 2027 and maintain ongoing engagement with the successor to the EU's research funding programme, Horizon 2020.
- The Life Sciences Industrial Strategy Implementation Committee should deliver an accelerated national plan for Digital Innovation Hubs, focusing on interoperability
- Improved collaboration and engagement with industry across the NHS and research landscape